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Cognitive Function Does Not Worsen During Pegylated
Interferon and Ribavirin Retreatment of Chronic
Hepatitis C
Robert J. Fontana,1 Linas A. Bieliauskas,2,3 Karen L. Lindsay,4 Carla Back-Madruga,5 Elizabeth C. Wright,6
Kristin K. Snow,7 Anna S.F. Lok,1 Ziad Kronfol,2 Latha Padmanabhan,7 and the HALT-C Trial Group
Treatment of chronic hepatitis C with pegylated interferon (peginterferon) and ribavirin can
cause or exacerbate depression but its effects on cognitive function are largely unknown. The
aim of this study was to determine whether treatment with peginterferon and ribavirin
adversely impacts cognitive function in patients with chronic hepatitis C. Prior nonre-
sponders to interferon were retreated with peginterferon alfa-2a and ribavirin for 24 (n 
177) or 48 weeks (n  57) in the Hepatitis C Antiviral Long-term Treatment Against
Cirrhosis trial. Cognitive function was prospectively assessed using a battery of 10 standard-
ized neuropsychological tests at weeks 0, 24, 48, and 72. Cognitive impairment was defined
based upon a global deficit score. The Beck Depression Inventory and Brief Symptom
Inventory were used to assess mood status. The 57 subjects who completed 48 weeks of
antiviral therapy reported significant increases in difficulty concentrating, emotional dis-
tress, and symptoms of depression, all of which improved after cessation of therapy [P <
0.0001, analysis of variance (ANOVA)]. Nonetheless, the frequency of cognitive impairment
did not increase during the first 24 weeks of treatment in 177 patients (34% versus 32%, P 
0.64) nor in the 57 patients completing 48 weeks of treatment (P  0.48, ANOVA). Con-
clusion: Retreatment of prior non-responders with peginterferon and ribavirin was not
associated with objective evidence of cognitive impairment as measured by a comprehensive
battery of neuropsychological tests. The lack of cognitive impairment is reassuring and
suggests that self-reported symptoms of cognitive dysfunction are more likely related to the
systemic and psychiatric side effects of antiviral treatment rather than measurable changes in
cognition. (HEPATOLOGY 2007;45:1154-1163.)
Abbreviations: ANOVA, analysis of variance; BDI, Beck Depression Inventory; CVMT, continuous visual memory test; GDS, global deficit score; GSI, global severity index;
HALT-C, Hepatitis C Antiviral Long-term Treatment against Cirrhosis; IFN, interferon; peg IFN, pegylated interferon; SS, standard score; WCST, Wisconsin card sorting test.
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The combination of pegylated interferon (pegin-terferon) and ribavirin is now considered the op-timal therapy for chronic hepatitis C.1,2 A 48-
week course of this combination results in sustained
eradication of hepatitis C virus (HCV) RNA from serum
in approximately 50% of patients.1,2 Peginterferon and
ribavirin may also be successful in selected nonresponders
or relapsers to standard interferon with or without ribavi-
rin.3 Combination therapy, however, is associated with
considerable side effects that can be dose limiting and lead
to dose reductions in 40% and early discontinuation in up
to 20% of treated patients.1,2,4 Side effects of combination
therapy include fatigue, muscle aches, hemolytic anemia,
bone marrow suppression, exacerbation of autoimmune
disorders, and a spectrum of neuropsychiatric complica-
tions.4,5 Mood disorders such as depression, anxiety, and
irritability are particularly common and reported in up to
50% of treated patients but can improve with peginter-
feron dose reductions and adjuvant medications.6 Many
patients also complain of “cloudy thinking” and describe
difficulties in word finding, memory, and concentration,
suggesting possible impairment of cognitive function, but
prospective studies using objective measures of cognitive
function have not been reported.7,8 Subtle abnormalities
in cognitive function have also been described in patients
with chronic hepatitis C not receiving antiviral thera-
py.8-10 The cause of these abnormalities is not known;
however, possibilities include a direct effect of HCV,
which may replicate in neurons as well as the effects of
systemic cytokines, concomitant psychiatric disease, and
subclinical hepatic encephalopathy.11
The Hepatitis C Antiviral Long-term Treatment
Against Cirrhosis Trial (HALT-C) is a prospective mul-
ticenter study designed to investigate the potential benefit
of maintenance therapy with peginterferon in reducing
the rate of clinical outcomes in prior nonresponders with
advanced fibrosis.3,12 Initially, all patients were treated
with peginterferon alfa-2a and ribavirin for 24 weeks in
the “lead-in phase.” Subjects who remained viremic at
week 20 were eligible for entry into the randomized phase
of the HALT-C trial, while subjects with undetectable
HCV RNA by PCR continued in the “responder arm” of
the study and were given a complete 48-week course of
combination antiviral treatment. The cognitive study
conducted at 2 of the HALT-C sites was designed to
prospectively assess neuropsychiatric parameters before,
during, and after treatment in the lead-in and responder
arms of the study and in the randomized phase. Using a
battery of 10 standardized neuropsychological tests, we
hypothesized that patients receiving peginterferon and
ribavirin would demonstrate evidence of reversible cogni-
tive impairment.13,14 We also hypothesized that patients
with low cognitive scores at baseline and those experienc-
ing depression on treatment would have the greatest inci-
dence and severity of cognitive impairment. In this work,
the results of neuropsychological testing in 177 patients
who received peginterferon and ribavirin for 24 weeks
during the lead-in phase and in 57 subjects who received
48 weeks of antiviral treatment in the responder arm of
the HALT-C trial are reported.
Patients and Methods
Patient Population
Inclusion criteria for the HALT-C trial include the
presence of detectable HCV RNA in serum, a liver biopsy
within 12 months of enrollment demonstrating bridging
hepatic fibrosis or cirrhosis, and lack of a sustained re-
sponse to a prior course of standard interferon with or
without ribavirin.3,12 Patients with any other liver disor-
ders or hepatic decompensation (Child-Turcotte-Pugh
score 6, history of variceal hemorrhage, ascites, or he-
patic encephalopathy) were excluded. Additional exclu-
sion criteria included intolerance to interferon, anti-HIV
reactivity, active alcohol or injection drug abuse, suicide
attempt or hospitalization for depression within the past 5
years, and a history of a severe or uncontrolled psychiatric
condition within the past 6 months. Participants in the
HALT-C trial enrolled at the University of Michigan and
University of Southern California were asked to also par-
ticipate in this prospective study of cognitive testing at
baseline, week 24, week 48, and week 72 of treatment. All
details of this study were approved by the local Institu-
tional Review Board and all patients gave written in-
formed consent.
Baseline Assessment
Years of education, occupation, and baseline medica-
tion use were recorded. Lifetime psychiatric history was
obtained using the computerized Composite Interna-
tional Diagnostic Interview (CIDI-LT).15 A semiquanti-
tative estimate of lifetime alcohol consumption was
obtained using an adaptation of the Skinner survey.16
HALT-C Study Design
All subjects were treated with peginterferon alfa-2a at a
dose of 180 g per week (Pegasys; Roche Laboratories,
Nutley, NJ) and ribavirin in doses of 1.0 to 1.2 g per day
(Copegus, Roche Laboratories). Serum HCV RNA test-
ing was done using the quantitative COBAS Amplicor
HCV Monitor test v.2.0 (Roche Molecular Diagnostics,
Branchburg, NJ), which has a lower limit of detection of
600 IU/mL. All samples with undetectable HCV RNA on
the quantitative assay were retested with the qualitative
COBAS Amplicor HCV test v.2.0 (Roche Molecular Di-
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agnostics, Branchburg, NJ), which has a lower limit of
detection of 100 IU/mL. Patients who failed to clear se-
rum HCV RNA by week 20 were randomized at week 24
to receive low dose peginterferon (90 g per week) or no
therapy for the next 3.5 years. Patients who tested HCV
RNA-negative at week 20 were considered virological re-
sponders and continued with combination antiviral ther-
apy for 48 weeks in the responder arm of the study.
Repeat HCV RNA testing was obtained at weeks 48 and
72. Subjects with undetectable HCV RNA at week 72
were considered to have achieved a sustained virological
response.
Cognitive Function
A battery of 10 standardized neuropsychological tests
with alternate forms when available were administered in
a predetermined order at weeks 0, 24, 48, and 72.9,17 The
battery included tests designed to assess differing domains
of cognitive function as follows: verbal memory using the
selective reminding test; nonverbal memory using the
continuous visual memory test; speed and efficiency of
information processing using the serial digit learning,
digit span test, and digit symbol test from the Wechsler
Adult Intelligence Scale; visuomotor tracking using the
simple reaction time, choice reaction time, and Trail’s A
and B; executive function using the Wisconsin card sort-
ing test (WCST); and verbal processing using the Con-
trolled Oral Word Association test (COWAT). The test-
retest reproducibility varied from 0.62 for simple reaction
time to 0.78 and 0.85 for digits forward and backward,
respectively, and 0.80 and 0.92 for Trail’s A and B, re-
spectively.18 The Shipley Institute of Living scale was ad-
ministered at baseline and a full-scale intelligence
quotient estimate from the Wechsler Adult Intelligence
Scale-Revised was calculated using population controls
with a mean of 100 and SD of 15.19 Standard scores (SSs)
were calculated for each neuropsychological test using
normative data.
Cognitive impairment was defined by a global deficit
score (GDS), which was calculated as the mean of the SSs
of the component tests and strongly correlated with clini-
cian assessment.17 A GDS of 1.0, which represents a
mean SS of 1 SD below the population mean on each
individual test was chosen as our criteria for cognitive
impairment. A GDS of 2.0 represents a mean SS of 2 SD
below the mean of each individual test and a GDS of 3.0
represents a mean SS that is 3 SD below the mean of each
test.
Mood Status
The Beck Depression Inventory-II (BDI-II) was used
to assess mood at weeks 0, 4, 12, 24, 36, 48, and 72.20 The
BDI-II scores were coded as follows: no depression, 10;
minimal depression, 11 to 14; mild depression, 15 to 19;
moderate depression, 20 to 28; and severe depression,
29. The brief symptom inventory was used to assess
emotional distress at the same times.21 Subjects were clas-
sified as having clinically significant emotional distress if
the global severity index (GSI) T-score was 63 (i.e.,
ninetieth percentile).
Data Analyses
Descriptive statistics of baseline demographic, clinical,
and liver disease parameters are reported as mean  SD or
median and range. Changes in mean GDSs over time
were assessed using repeated measures ANOVA (SAS
Proc Mixed version 9.1). Similarly, change in the propor-
tion with cognitive impairment over time was assessed
using a repeated measures logistic regression analysis (SAS
Proc Glimmix version 9.1). Change over time from week
0 to week 24 was assessed in the 177 patients with com-
plete week 24 data. Change over the 4 time points of
weeks 0, 24, 48, and 72 was assessed in the 57 patients in
the responder arm with data available through week 72.
Results
Study Population
A total of 201 subjects were enrolled in the cognitive
study at the 2 participating sites and were treated with
peginterferon and ribavirin. At week 24, 177 subjects
completed the cognitive testing while the remaining 24
subjects had either withdrawn from the HALT-C trial
(n  14), withdrawn from the cognitive study (n  5), or
had incomplete testing (n  5) (Fig. 1). The demographic
features and baseline cognitive scores of the 24 patients
who did not complete the week 24 testing were not sig-
nificantly different from those who remained in the study
(data not shown). Among the 177 subjects completing 24
weeks of treatment in the lead-in phase, 68 were week 20
virological responders with undetectable HCV RNA and
continued in the responder arm of the trial and 62 and 57
of them completed cognitive testing at weeks 48 and 72,
respectively. The remaining 109 week 20 virological non-
responders had treatment discontinued at week 24 and
were eligible for entry into the randomized phase of the
HALT-C trial.
The baseline features of the 177 HALT-C patients that
completed cognitive testing at weeks 0 and 24 were sim-
ilar to the baseline features of the 57 subjects who com-
pleted 48 weeks of antiviral therapy and cognitive testing
at week 72 (Table 1). A majority of the patients were
Caucasian men infected with HCV genotype 1. The
mean Shipley intelligence quotient scores of the HALT-C
patients were normally distributed and similar to that of
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the general United States population (i.e., mean U.S.
score  100  15), suggesting that the general intellec-
tual abilities of this patient cohort was not reduced as a
group.22 Nonetheless, a substantial proportion had evi-
dence of cognitive impairment at baseline as defined by a
GDS exceeding 1.0. Specifically, 32% of the 177
HALT-C subjects in the lead-in cohort and 25% of the
week 20 virological responders had cognitive impairment
with alterations in verbal recall and working memory at
week 0, while other domains of cognitive function, in-
cluding visuomotor tracking and executive function, re-
mained largely intact (Table 2). Although the majority of
patients had normal BDI-II scores (i.e., 11), 30% of the
lead-in patients and 26% of the responder arm patients
were receiving either an anxiolytic or antidepressant med-
ication at baseline. However, there was no significant re-
lationship between the use of these medications and
cognitive impairment at baseline (P  0.79).
Changes in Cognitive Function Through Treatment
Week 24
Contrary to expectations, the overall frequency of cog-
nitive impairment remained unchanged in the 177 pa-
tients receiving antiviral therapy during the lead-in phase
of the HALT-C trial (32% at week 24 versus 34% at week
0, P  0.64) (Fig. 2). More specifically, 22 of the 120
patients (18%) without cognitive impairment at week 0
met criteria for impairment at week 24 with a GDS 1.0.
However, 19 of the 57 patients (33%) with cognitive
impairment at week 0 were no longer impaired at week
24. Thus, there was no net increase in the frequency of
cognitive impairment at week 24 compared to week 0. In
addition, there was no significant change in the mean
GDS at weeks 0 and 24 (0.76 versus 0.75, P  0.84).
Furthermore, there was no correlation between the week
20 virological response and cognitive impairment at week
24 (Fig. 2). There was also no significant relationship
between the total dose of peginterferon and ribavirin re-
ceived and the incidence of cognitive impairment during
the first 24 weeks of treatment (data not shown). Re-
ported reasons for peginterferon dose reductions in 106
patients included myelotoxicity (65%), fatigue (22%),
mood disorders (14%), and other reasons (20%), while
indications for ribavirin dose reductions in 108 patients
included anemia (67%), fatigue (19%), cough (18%),
and other reasons (21%). Finally, there was no significant
relationship between changes in the BDI-II score and the
incidence of cognitive impairment (P  0.18).
Changes in Cognitive Function Through Week 72 in
the Responder Arm
Among the 57 patients who received 48 weeks of anti-
viral therapy, there was no significant increase in the in-
cidence of cognitive impairment over time (P  0.48,
ANOVA) (Fig. 3). In addition, the mean GDSs also re-
mained unchanged over time (data not shown). Although
subjects who experienced a virological relapse or break-
through at week 72 tended to have a higher incidence of
cognitive impairment at week 24, the incidence of impair-
ment through week 72 was not significantly different
from subjects with a sustained virological response (Fig.
3). Analysis of the individual neuropsychological test re-
sults demonstrated that the SSs actually improved on the
continuous visual memory test (CVMT), Digit Span,
Digit Symbol, Trail’s B, and the WCST at various times
compared to baseline (Table 2). In particular, the SSs of
the CVMT and Trail’s B tests significantly increased at
weeks 24, 48, and 72 compared to baseline. In compari-
son, the improvements in the SSs of the Digit Symbol,
Digit Span, and the WCST were less dramatic and con-
sistent. Adherent subjects who received at least 80% of the
intended doses of peginterferon and ribavirin through
week 48 were not more likely to develop evidence of cog-
nitive impairment compared to nonadherent subjects
(data not shown).
Changes in Mood Status and Emotional Distress
Through Week 72 in the Responder Arm
The mean BDI-II scores of the 57 patients who re-
ceived 48 weeks of therapy significantly increased at weeks
24 and 48 compared to baseline and then subsequently
improved off-treatment at week 72 (P  0.0002 by re-
Fig. 1. Patient population. At week 24, 177 of the 201 chronic
hepatitis C patients enrolled in the HALT-C cognitive study underwent
repeat neuropsychological testing. The 68 patients who suppressed HCV
RNA to undetectable levels at week 20 continued on peginterferon and
ribavirin for a total of 48 weeks. At week 72, 57 responder arm subjects
underwent a final neuropsychological evaluation.
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peated measures ANOVA) (Fig. 4). Similarly, the mean
GSI score, which reflects emotional distress, significantly
increased during treatment in the 57 responder patients
and subsequently improved off-treatment at week 72
(P  0.0001 by repeated measures ANOVA) (data not
shown). The proportion of patients with clinically signif-
icant emotional distress defined as a GSI score 63 also
significantly increased over time from 11% at week 0 to
14% and 25% at weeks 24 and 48, respectively, and then
returned to 12% at week 72 (P  0.043) (data not
shown). Analysis of specific questions addressing diffi-
culty concentrating and indecisiveness from the BDI-II
also demonstrated significant worsening during antiviral
therapy, which improved off-treatment (Fig. 5).
Discussion
Previous studies have demonstrated frequent and
problematic neuropsychiatric toxicity in oncology pa-
tients receiving high daily doses of standard interferon,
including depression and anxiety.23-25 In some oncology
patients, cognitive impairment during interferon therapy
was severe and disabling and persisted even after treat-
ment was discontinued.26 The pattern of described cog-
nitive abnormalities is suggestive of a frontal or
subcortical effect of interferon that may be due to changes
in central adrenergic or serotonergic neurotransmission or
cerebral blood flow.27 Clinical trials of peginterferon and
ribavirin for chronic hepatitis C also reported high rates of





Age (yr) 50.2  7.8 49.4  7.4
Male (%) 69 68
Ishak fibrosis 5/6 (%) 37 25
HCV RNA (log10 IU/ml) 6.5  0.5 6.5  0.6
HCV genotype 1 (%) 87 81
Ethnicity
White (%) 71 84
Black (%) 14 4
Other (%) 3 4
Hispanic (%) 12 9
Educational level (1-16 yr) 10.5  2.2 10.3  2.2
At least high school (%) 89 89
At least college (%) 24 18
Occupational level (1-6) 4.0  1.6 4.0  1.4
1  Unskilled labor, farm labor (%) 2 0
2  Semiskilled, operative, service (%) 27 23
3  Not in work force  10 yr (%) 11 13
4  Skilled labor/craftsman/foreman (%) 13 21
5  Manager/clerical/ sales work (%) 26 25
6  Professional/technical (%) 21 18
Intelligence quotient 99.5  12.7 101.6  12.1
Diabetes mellitus (%) 25 28
Prior IFN  ribavirin (%) 69 53
Week 0 on antidepressant/anxiolytic (%) 30 26
Week 0 global deficit score 0.76  0.6 0.70  0.7
Global deficit score 1 (%) 32 25
Week 0 BDI-II score 6.2  6.2 5.9  6.0
% 11 79 81
% 11–14 8 9
% 15–19 7 5
% 20–28 5 5
% 29 1 0
Week 0 GSI score 51.2  11.5 51.4  10.8
GSI score 63 (%) 15 11
Taking 80% pegIFN and ribavirin (week 0 to 20) (%) 46 51
Taking 80% pegIFN (week 0 to 20) (%) 70 81
Taking 80% ribavirin (week 0 to 20) (%) 63 61
Taking 80% pegIFN and ribavirin (week 0 to 48) (%) NA 42
Taking 80% pegIFN (week 0 to 48) (%) NA 70
Taking 80% ribavirin (week 0 to 48) (%) NA 60
NOTE: Results reported as mean  SD or %.
Abbreviation: IFN, interferon; pegIFN, peginterferon (pegylated interferon)
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mood disorders and self-reported symptoms of difficulty
thinking and concentrating, fatigue, and depression.2,5,28
Therefore, we postulated that chronic hepatitis C patients
receiving antiviral therapy in the HALT-C study would
demonstrate an increasing frequency of cognitive impair-
ment using a comprehensive battery of 10 neuropsycho-
logical tests.8 However, the frequency of cognitive
impairment did not increase at week 24 compared to
baseline in the 177 patients completing the lead-in phase
(Fig. 2). In addition, the frequency of impairment did not
increase through week 48 compared to baseline in the 57
responder arm patients, despite statistically and clinically
significant increases in depression and emotional distress
scores (Figs. 3 and 4). Finally, there was no significant
relationship between viral suppression and the frequency
or severity of cognitive impairment during the lead-in and
responder arms of the trial (Figs. 2 and 3).
The lack of new or worsening cognitive impairment
during antiviral treatment in the HALT-C study may
reflect differences in study design and methodology or the
dose of interferon used compared to previous studies of
oncology and chronic hepatitis C patients.26-28 The cur-
rent study was adequately powered since each subject was
compared to his or her pretreatment baseline status and
the total sample size exceeded that utilized in other studies
of chronic hepatitis C patients.2,5,28 A battery of 10 stan-
dardized neuropsychological tests was selected to detect
subtle changes in multiple domains of cognitive function
over time.7-9 In addition to comparing individual test
Table 2. Standard Scores of Individual Neuropsychological Tests in 57 Patients Completing 48 Weeks of Antiviral Therapy
Test Week 0 Week 24 Week 48 Week 72
Selective reminding test SS 31.42 (15.1) 30.35 (16.7) 32.85 (15.8) 32.33 (17.9)
CVMT SS 42.92 (14.5) 48.23 (16.3)* 53.50 (15.5)* 54.47 (14.6)*
Digit span SS 43.92 (7.5) 44.72 (7.9)* 46.55 (11.0)* 44.92 (7.4)
Digit symbol SS 47.58 (8.8) 47.68 (9.6) 49.65 (10.4) 53.07 (10.5)*
Serial digit learning SS 38.73 (17.9) 37.58 (18.4) 36.17 (19.0) 41.25 (18.0)
Trail’s A SS 48.14 (12.8) 49.72 (11.8) 51.61 (13.52) 53.37 (12.7)
Trail’s B SS 46.96 (16.4) 49.24 (13.9)* 51.47 (14.1)* 54.28 (14.5)*
Finger tapping test SS 56.86 (14.4) 55.39 (14.8) 58.34 (12.2) 56.83 (11.3)
WCST SS 47.93 (13.6) 47.92 (14.7) 49.80 (13.1)* 51.75 (9.9)*
COWAT SS 54.70 (10.1) 52.78 (9.6)† 54.81 (11.4) 58.35 (10.5)*
Simple reaction time (msec) 352.6 (78.6) 384.1 (102.4)* 396.8 (88.5)* 367.1 (90.6)
Choice reaction time (msec) 494.5 (130.4) 499.9 (105.5) 504.8 (103.1) 492.7 (106.1)
Simple reaction time 425 msec (%) 20 25 33* 21
Choice reaction time 550 msec (%) 29 25 30 25
NOTE: All SSs reported as mean (SD).
Abbreviations: COWAT, Controlled Oral Word Association test; SS, standard score.
*SS significantly better (higher) compared to week 0 at P  0.05.
†SS significantly poorer (lower) compared to week 0.
Fig. 2. Cognitive impairment during the lead-in phase of HALT-C. The
frequency of cognitive impairment in the 177 patients treated in the
lead-in phase of HALT-C did not significantly change between week 0 and
week 24 (32% versus 34%, P  0.64). In addition, the frequency of
impairment did not correlate with suppression of HCV RNA to undetect-
able levels in the 68 virological responders compared to the 109 patients
who remained HCV RNA-positive (P  0.58).
Fig. 3. Cognitive impairment in the responder arm of HALT-C. The
frequency of cognitive impairment in the 57 HALT-C patients treated for
48 weeks did not significantly change over time (P  0.48). Although the
22 subjects without a sustained virological response (SVR) tended to
have a higher incidence of impairment at week 24 compared to the 35
with an SVR, this trend was not statistically significant (P  0.28).
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scores over time, a GDS previously shown to correlate
with clinician assessment was used to define cognitive
impairment.17 It is possible that the early studies of on-
cology patients were methodologically flawed or not rep-
resentative of the neurotoxic profile of standard doses of
peginterferon used to treat chronic hepatitis C patients.
For example, in a randomized controlled study of stan-
dard interferon given for 36 months to 75 melanoma
patients, there was no evidence of worsening cognitive
function despite increased anxiety over time in the inter-
feron treated group compared to the untreated group.29
Small pilot studies in HIV as well as chronic hepatitis C
patients receiving standard interferon at low to moderate
doses (i.e., 3 to 6 million units 3 times a week) also failed
to show any significant changes in cognitive function de-
spite development of neurophysiological abnormalities in
some.30-32 Therefore, the literature on the effects of inter-
feron therapy on cognitive function is mixed at best, and
our initial hypotheses based upon the published reports of
high dose interferon therapy in oncology patients may
have been incorrect. In addition, the selection of patients
with demonstrated tolerance to prior interferon therapy
in the HALT-C study may have precluded us from ob-
serving an adverse effect of treatment on cognitive func-
tion. Nonetheless, 7% of the lead-in patients prematurely
discontinued treatment due to severe side effects and 30%
and 37% of the lead-in patients required a peginterferon
or ribavirin dose reduction, respectively, due to side ef-
fects that were most commonly due to myelotoxicity or
fatigue (Table 1).
An alternative explanation for the lack of cognitive
impairment observed in the current study is the potential
for practice effects when neuropsychological tests are ad-
ministered repeatedly over time.33,34 At least several of the
tests used in our battery (i.e., Trail’s test, Finger Tapping
test, Digit Span forward, Reaction time) have been re-
ported to lack significant practice effects.35 To minimize
potential practice effects in the current study, tests with
alternate forms were selected whenever possible (e.g., 4
forms of the Selective reminding test) and the tests were
administered in a predetermined order.36 The testing was
also spaced as far apart in time as possible (e.g., every 6
months), yet still allowing us to study the effects of a
48-week course of antiviral therapy. Upon careful inspec-
tion of the SSs of the 10 tests administered, the mean SS
Fig. 5. Self-reported symptoms of cognitive dysfunction during com-
bination antiviral treatment (from the BDI-II). (A) Indecisiveness. Subjects
reported a significant increase in difficulty making decisions while re-
ceiving antiviral therapy compared to baseline (Scale 0 to 3: 0  make
decisions well; 3  trouble making decisions) (week 12, week 24, week
36, and week 48 versus week 0, P  0.05, McNemar’s test). (B)
Difficulty concentrating. Subjects reported a significant increase in diffi-
culty concentrating during antiviral therapy compared to baseline which
improved after treatment cessation (Scale 0 to 3: 0  concentrate well;
3  can’t concentrate on anything) (week 12, week 24, week 36, and
week 48 versus week 0, P  0.05, McNemar’s test). (Data plotted as
mean  SD).
Fig. 4. Beck depression scores. The mean Beck scores of the 57
patients receiving 48 weeks of peginterferon and ribavirin significantly
increased during antiviral therapy and then returned to their pretreatment
values at week 72 (P  0.0002).
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of the Trail’s B and the CVMT demonstrated statistically
significant improvements over time (Table 2). Prior stud-
ies have shown that figural memory tests, which measure
a similar cognitive domain as the CVMT, demonstrate a
significant practice effect on short-term readministration,
while practice effects have generally not been reported for
Trail’s B.36,37 Nevertheless, practice effects based upon
procedural learning, (i.e., improved performance due to
increasing familiarity with the test rules), cannot be ex-
cluded, particularly in this cohort of generally well-edu-
cated patients with high levels of occupational
functioning.38,39 Future longitudinal studies of cognitive
function in chronic hepatitis C patients should incorpo-
rate tests with multiple alternate forms as well as a control
group of patients not receiving antiviral therapy to mini-
mize any potential procedural learning or practice effects.
Prior studies have demonstrated a high prevalence of
mood disorders among chronic hepatitis C patients prior
to treatment, as was seen in our study population (Table
1).5-7 In addition, clinically and statistically significant
decrements in health-related quality of life have con-
sistently been reported with interferon and ribavirin
therapy.5,40 Hilsabeck et al.32 recently demonstrated that
chronic hepatitis C patients frequently complain of sub-
jective symptoms of impaired cognition during antiviral
therapy that are not related to objective performance on
neuropsychological tests, but are associated with symp-
toms of depression, anxiety, and fatigue. Similarly, mul-
tiple studies of epilepsy and multiple sclerosis patients
demonstrate a consistently stronger relationship between
subjective cognitive complaints with measures of depres-
sion and anxiety than with performance on objective neu-
ropsychological tests.41-44 Therefore, it is possible that the
battery of neuropsychological tests used in this study and
others do not adequately measure the everyday problems
in short-term memory that patients notice the most. Our
data clearly demonstrates an increased frequency of de-
pression and emotional distress during treatment, and
symptoms of difficulty concentrating and making deci-
sions (Figs. 4 and 5). Therefore, self-reported symptoms
of cognitive impairment and difficulty thinking during
antiviral treatment may reflect psychiatric side-effects and
mood disorders resulting from treatment rather than im-
pairment of cognitive function as measured by the test
battery. Alternatively, the assessment of cognitive func-
tion using a battery of objective tests may not adequately
capture the cognitive demands and challenges of everyday
life that chronic hepatitis C patients experience during
antiviral therapy.44 To further explore these issues, studies
using standardized assessment of subjective cognitive
symptoms during antiviral treatment compared to mood
status and objective performance on a battery of neuro-
psychological tests are needed.
The lack of impaired cognition during peginterferon
and ribavirin treatment is reassuring to the many chronic
hepatitis C patients in need of future therapy. In fact, fear
of medication side-effects may preclude many patients
and physicians from considering antiviral treatment alto-
gether. Other investigators have suggested that the pres-
ence of replicating HCV in the body and particularly in
the brain may contribute to the high incidence of mood
disorders, impaired cognition, and reduced quality of life
reported in chronic hepatitis C patients compared to un-
infected controls.10,45,46 The lack of a correlation between
HCV RNA suppression with objective measures of cog-
nitive function in the current study may, in part, be due to
the small number of patients enrolled or to the lack of a
true biological effect of HCV replication on cognitive
function. In patients with myeloproliferative disorders
who are prothrombotic and have cognitive impairment,
improved cognitive function has been reported following
interferon treatment, presumably due to improved cere-
bral blood flow and oxygenation.47 Similarly, use of inter-
feron beta to treat multiple sclerosis patients has been
associated with improved cognition, presumably due to
reduced cerebral inflammation.48 In patients with chronic
hepatitis C, the effect of interferon therapy on brain func-
tion may be complex, in that any improvement due to
suppression of HCV replication may be offset by the con-
comitant development of serotonin depletion with result-
ant mood disorders, leading to no discernible net change
in cognition.49,50 Additional prospective studies assessing
central neurotransmission, blood flow, and physiology,
along with cognitive function during antiviral therapy,
appear warranted to further explore these hypotheses.
In summary, no significant change in cognitive func-
tion was observed in the 177 prior nonresponders re-
treated with peginterferon and ribavirin for 24 weeks in
the HALT-C study. In addition, the 57 week 20 virolog-
ical responders who completed a 48-week course of anti-
viral treatment also failed to demonstrate any significant
increase in the frequency or severity of cognitive impair-
ment. Therefore, the common complaint of difficulty
thinking and concentrating during antiviral therapy may
relate more to the systemic side-effects of treatment (i.e.,
fatigue, mood disorders) rather than direct effects of
peginterferon on cognitive function as measured on a bat-
tery of objective neuropsychological tests.
Acknowledgment: In addition to the authors of this
manuscript, the following individuals were instrumental
in the planning, conduct and/or care of patients enrolled
in this study at each of the participating institutions, as
HEPATOLOGY, Vol. 45, No. 5, 2007 FONTANA ET AL. 1161
follows: University of Southern California, Los Angeles,
CA (Contract N01-DK-9-2325, Grant M01RR-00043):
Carol B. Jones, R.N., Susan L. Milstein, R.N., and the
USC Neuropsychology Technicians; University of Mich-
igan Medical Center, Ann Arbor, MI (Contract N01-
DK-9-2323, Grant M01RR-00042): Pamela Richtmyer,
B.S., L.P.N., C.C.R.C., Erin Ford, B.S., Leslie Giudotti,
Emily Anderson; New England Research Institutes, Wa-
tertown, MA (Contract N01-DK-9-2328): Teresa M.
Curto, M.S.W., Margaret C. Bell, R.N., M.S., M.P.H.;
National Institute of Diabetes and Digestive and Kidney
Diseases, Division of Digestive Diseases and Nutrition,
Bethesda, MD: Leonard B. Seeff, M.D., Patricia R. Ro-
buck, Ph.D., Jay H. Hoofnagle, M.D., James E. Everhart,
M.D.
References
1. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M,
Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with
interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C:
a randomized trial. Lancet 2001;358:958-965.
2. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et
al. Peginterferon-2a and ribavirin combination therapy in chronic hepa-
titis C. Ann Intern Med 2004;140;346-355.
3. Shifffman ML, DiBisceglie AM, Lindsay KL, Morishima C, Wright EC,
Everson GT, et al. Peginterferon alfa-2a and ribavirin in patients with
chronic hepatitis C who failed prior treatment. Gastroenterology 2004;
126:1015-1023.
4. Lee SS, Peltekian K, Krajdens M, Yoshida EM, Deschenes M, Heathcote
EJ, et al. Treating chronic hepatitis C with pegylated interferon alfa-2a
(40kD) and ribavirin in clinical practice. Aliment Pharmacol Ther 2006;
23:397-408.
5. Fried MW, Russo MA. Side effects of antiviral therapy for hepatitis C.
Gastroenterology 2003;124:1711-1719.
6. Fontana RJ. Neuropsychiatric toxicity of antiviral treatment in chronic
hepatitis C. Dig Dis 2000;18;107-116.
7. Hilsabeck RC, Hassanein TI, Carlson MD, Ziegler EZ, Perry W. Cogni-
tive functioning and psychiatric symptomatology in patients with chronic
hepatitis C. J Int Neuropsychol Soc 2003;9:847-854.
8. Weissenborn K, Krause J, Bokemyer M, Hecker H, Schuler A, Anen JC, et
al. Hepatitis C virus infection affects the brain: evidence from psychomet-
ric studies and magnetic resonance spectroscopy. J Hepatol 2004;41:845-
851.
9. Fontana RJ, Bieliauskas LA, Back-Madruga C, Lindsay KL, Kronfol Z,
Lok ASF, et al. Cognitive function in hepatitis C patients with advanced
fibrosis enrolled in the HALT-C trial. J Hepatol 2005;43:614-622.
10. Forton DM, Thomas HC, Murphy CA, Allsop JM, Foster GR, Main J, et
al. Hepatitis C and cognitive impairment in a cohort of patients with mild
liver disease. Hepatology 2002;35:433-439.
11. McAndrews MP, Farcnik K, Carlen P, Damyanovich A, Mrkonjic M,
Jones S, Heathcote EJ. Prevalence and significance of neurocognitive dys-
function in hepatitis C in the absence of correlated risk factors. Hepatology
2005;41:801-808.
12. Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman
ML, et al. Evolution of the HALT-C trial: pegylated interferon as a main-
tenance therapy for chronic hepatitis C in previous Interferon nonre-
sponders. Control Clin Trials 2004;25:472-492.
13. Adams F, Quesada JR, Gutterman JU. Neuropsychiatric manifestations of
human leukocyte interferon therapy in patients with cancer. JAMA 1984;
252;938-941.
14. Meyers CA, Scheibel RS, Forman AD. Persistent neurotoxicity of system-
ically administered interferon-alpha. Neurology 1991;41:672-676.
15. Wittchen HU. Reliability and validity studies of the WHO composite
international diagnostic interview: a critical review. J Psychiatr Res 1994;
28:57-84.
16. Skinner HA, Sheu WJ. Reliability of alcohol use indices: the lifetime drink-
ing history and the MAST. J Stud Alcohol 1982;43:1157-1170.
17. Bieliauskas L, Back-Madruga C, Lindsay KL, Snow KK, Kronfol Z, Lok
ASF, et al. Clinical relevance of cognitive scores in patients with advanced
fibrosis. J Clin Exp Neuropsychol 2006;28:1346-1361.
18. McCaffrey RJ, Ortega A, Orsillo SM, Nelles WB, Haase RF. Practice
effects in repeated neuropsychological assessments. Clin Neuropsychol
1991;6:32-42.
19. Zachary RA. Shipley institute of living scale. Los Angeles: Western Psy-
chological Services, 1991:1-35.
20. Beck AT, Steer RA, Brown GK. BDI-II Manual. The Psychological Cor-
poration. San Antonio, TX: Harcourt Brace and Company, 1996:1-20.
21. Derogatis LR, Melisaratos N. The brief symptom inventory: an introduc-
tory report. Psychol Med 1983;3:595-605.
22. U.S. Census Bureau, Population Division, Education & Social Stratifica-
tion Branch. Maintained by: Information & Research Services Internet
Staff (Population Division). Created: March 15, 2004.
23. Pavol MA, Meyers CA, Rexer JL, Valentine AD, Mattis RJ, Talpaz M.
Pattern of neurobehavioral deficits associated with interferon-alfa therapy
for leukemia. Neurology 1995;45:947-950.
24. Merimsky O, Reider-Groswasser I, Inbar M, Chaitchik S. Interferon-re-
lated mental deterioration and behavioral changes in patients with renal
cell carcinoma. Eur J Cancer 1990;26:596-600.
25. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK,
Penna S, Goodkin RS, et al. Paroxetine for the prevention of depression
induced by high-dose interferon alfa. N Engl J Med 2001;344:961-
966.
26. Meyers CA, Scheibel RS, Forman AD. Persistent neurotoxicity of
systemically administered interferon-alpha. Neurology 1991;41:672-
676.
27. Juengling FD, Ebert D, Gut O, Engelbrecht MA, Rasenack J,
Nitzsche EU, et al. Prefrontal cortical hypometabolism during low-
dose interferon alpha treatment. Psychopharmacology (Berl) 2000;
152:383-389.
28. Hollander A, Foster GR, Weiland O. Health-related quality of life before,
during and after combination therapy with interferon and ribavirin in
unselected Swedish patients with chronic hepatitis C. Scand J Gastroen-
terol 2006;41:577-585.
29. Caraceni A, Gangeri L, Martini C, Belli F, Brunelli C, Baldini M, et al.
Neurotoxicity of interferon-a in melanoma therapy: results from a ran-
domized controlled trial. Cancer 1998;83;482-489.
30. Mapou RL, Law WA, Wagner K, Malone JL, Skillman DK. Neuropsy-
chological effects of interferon alfa-n3 treatment in asymptomatic human
immunodeficiency virus-1-infected individuals. J Neuropsychiatry Clin
Neurosci 1996;8:74-81.
31. Amodio P, De Toni EN, Cavalletto L, Mapelli D, Bernardinello E. Del
Piccolo F, et al. Mood, cognition and EEG changes during interferon 
(alfa-IFN) treatment for chronic hepatitis C. J Affect Disord 2005;84:93-
98.
32. Hilsabeck RC, Hassanein TI, Ziegler EA, Carlson MD, Perry W. Effect of
interferon a on cognitive functioning in patients with chronic hepatitis C.
J Int Neuropsychol Soc 2005;11:16-22.
33. Collie A, Maruff P, Darby DG, McStephen M. The effects of practice on
the cognitive test performance of neurologically normal individuals as-
sessed at brief test-retest intervals. J Int Neuropsychol Soc 2003;9:419-
428.
34. Lemay S, Bedard M, Roleau I, Tremblay P. Practice effect and test-retest
reliability of attentional and executive tests in middle-aged to elderly sub-
jects. Clin Neuropsychol 2004;18:284-302.
35. McCaffrey RJ, Ortega A, Orsillo SM, Neiles WB, Haase RF. Practice
effects in repeated neuropsychological assessment. Clin Neuropsychol
1992;6:32-42.
1162 FONTANA ET AL. HEPATOLOGY, May 2007
36. Hannay HJ, Levin HS. Selective reminding test: an examination of
the equivalence of four forms. J Clin Exp Neuropsychol 1985;7:251-
263.
37. Basso MR, BornsteinRA, Lang JM. Practice effects of commonly used
measures of executive function across twelve months. Clin Neuropsychol
1999;13:283-292.
38. Beglinger LJ, Crawford-Miller, Kareken DA. Neuropsychological practice
effects and change detection in people with schizophrenia. Schizophr Res
2003;62:191-194.
39. Paradee CV, Rapport LJ, Hanks RA, Levy JA. Circadian preference and
cognitive functioning among rehabilitation inpatients. Clin Neuropsychol
2005;19:55-72.
40. Dan AA, Martin LM, Crone C, Ong JP, Farmer DW, Wise T, et al.
Depression, anemia, and health-related quality of life in chronic hepatitis
C. J Hepatol 2006;44:491-498.
41. Benedict RHB, Cox D, Thompson LL, Foley F, Weinstock-Guttman B,
Munschauer F. Reliable screening for neuropsychological impairment in
multiple sclerosis. Mult Scler 2004;10:675-678.
42. Randolph JJ, Arnett PA, Freske P. Metamemory in multiple sclerosis:
Exploring affective and executive contributors. Arch Clin Neuropsychol
2004;19:259-279.
43. Elixhauser A, Leidy NK, Meador K, Means E, Willan MK. The relation-
ship between memory performance, perceived cognitive function and
mood in patients with epilepsy. Epilepsy Res 1999;37:13-24.
44. Banos JH, LaGory J, Sawrie S, Faught E, Knowlton R, Prasad A, et al.
Self-report of cognitive abilities in temporal lobe epilepsy:cognitive, psy-
chosocial, and emotional factors. Epilepsy Behav 2004;5:575-579.
45. Forton DM, Allsop JM, Main J, Foster GR, Thomas HC, Taylor-Robin-
son SD. Evidence for a cerebral effect of the hepatitis C virus. Lancet
2001;358:38-39.
46. Radkowski M, Wilkinson J, Nowicki M, Adair D, Vargas H, Knguid C, et
al. Search for hepatitis C virus negative-strand RNA sequences and analysis
of viral sequences in the central nervous system: evidence of replication.
J Virol 2002;76:600-608.
47. Mayr N, Zeithofer J, Deecke L, Fritz E, Ludwig H, Gisslinger H. Neuro-
logical function during long-term therapy with recombinant interferon-
alpha. J Neuropsychiatry Clin Neurosci 1999;11:343-348.
48. Barak Y, Achiron A. Effect of interferon-beta-1b on cognitive function in
multiple sclerosis. Eur Neurol 2002;47:11-14.
49. Weissenborn K, Ennen JC, Bokemeyer M, Ahl B, Wurster U, Tillmann
HL, et al. Monoaminergic neurotransmission is altered in hepatitis C virus
infected patients with chronic fatigue and cognitive impairment. Gut
2006;55:1624-1630.
50. Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpe S, Maes M.
IDO and interferon-a induced depressive symptoms: a shift in hypoth-
esis from tryptophan depletion to neurotoxicity. Mol Psychiatry 2005;
10:538-544.
HEPATOLOGY, Vol. 45, No. 5, 2007 FONTANA ET AL. 1163
